IL17RA and Miyoshi myopathy: In MM, our gain of function assays demonstrated that re-expression of miR-192 markedly inhibited cell growth and metastasis capabilities, by suppressing IL-17R expression, indicating that miR-192 might be a promising therapeutic target for multiple types of cancer treatment, including MM.